Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT06180733
Title Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer (PAM-II)
Acronym PAM-II
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors University Medical Center Groningen
Indications
Therapies
Age Groups: senior | adult
Covered Countries NLD

Additional content available in CKB BOOST